Aiforia has been selected as an AI partner for the PROSTIA project - expands to five new hospitals in Paris
Aiforia Technologies Plc, Press Release, April 16, 2026 at 12:00 EEST
Aiforia has been selected as an AI partner for the PROSTIA project - expands to five new hospitals in Paris
Aiforia France, a subsidiary of Aiforia Technologies Plc, has been selected as the AI partner for the PROSTIA project led by Assistance Publique–Hôpitaux de Paris (AP-HP). This initiative will deploy Aiforia’s CE-IVD-marked prostate cancer diagnostic solution across all AP-HP pathology sites involved in the management of prostatic pathologies, expanding an ongoing collaboration initiated in 2024 at the AP-HP hospitals Bicêtre and Saint-Louis.
With the addition of five new hospitals, the project will enable the analysis of all 3,000 prostate biopsy cases per year performed within AP-HP using Aiforia’s AI technology, making it one of the first large-scale, real-world implementations of AI in routine pathology in Europe.
The new deals are part of the two-year PROSTIA project, funded by Bpifrance, a major strategic initiative supported by the national France 2030 program, aimed at evaluating the real-world impact of an AI-based diagnostic support tool for prostate cancer.
PROSTIA is a flagship initiative demonstrating how AI can be deployed at scale in real clinical settings, with a measurable impact on organizations and anatomical pathology workflows. The goal is to evaluate the medical, operational, and economic impacts of integrating AI into routine pathology workflows, specifically for the analysis of prostate biopsies. This medical-economic evaluation of the large-scale use of AI will provide the necessary data for considering future reimbursement for AI in pathology. In the longer term, the project aims to extend the use of artificial intelligence to other use cases.
“Our involvement in the PROSTIA project marks a significant milestone in bringing AI-augmented diagnostics to routine clinical practice in France. The project is crucial for laying the foundation for broader adoption of AI across other pathology use cases. France is a key market for us, and we are pleased to be the company that helps hospitals to implement AI in their pathology workflows,” says Jukka Tapaninen, CEO of Aiforia.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com